Bicycle Therapeutics vs Foghorn Therapeutics
BCYC and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCYC and FHTX compare
Bicycle Therapeutics is the larger company, worth 2.1 times as much as Foghorn Therapeutics ($224M against $109M).
Bicycle Therapeutics grew revenue faster over the last twelve months (195% versus 52.0% for Foghorn Therapeutics).
Bicycle Therapeutics keeps more of each dollar of sales as profit, with a net margin of −170% compared with −176% at Foghorn Therapeutics.
Bicycle Therapeutics scores higher on the StockData Score (11 against 9 for Foghorn Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCYC | FHTX |
|---|---|---|
| Size and price | ||
| Market cap | $224M | $109M |
| Share price | $3.20 | $1.83 |
| Change, 1 year | −50.6% | −61.0% |
| Change, 5 years | −94.1% | −86.6% |
| Beta (5Y) | 2.10 | 2.82 |
| Employees | 288 | 106 |
| StockData Score | ||
| Total score | 11 (better) | 9 |
| Valuation score | 3 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.7× (better) | 3.0× |
| P/B | 0.4× | – |
| FCF yield | −78.9% | −77.6% (better) |
| Fair value | $16.12 | – |
| Margin of safety | 80.1% | – |
| Growth | ||
| Revenue growth (TTM) | 195% (better) | 52.0% |
| Revenue growth, 5Y average | 47.5% | 135% (better) |
| Profitability | ||
| Operating margin | −189% (better) | −198% |
| Net margin | −170% (better) | −176% |
| FCF margin | −212% (better) | −229% |
| Return on equity | −25.2% | – |
| Return on invested capital | −4543% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −815.6× | – |
| Current ratio | 12.09 (better) | 3.36 |
| Altman Z-score | −0.08 (better) | −4.61 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 53.4% | 75.6% |
| Held by insiders | 21.3% | 36.3% |
| Insider net buying, 12 months | −$523K | – |
| Short interest, % of float | – | 6.0% |
Go deeper
- BCYC stock overview
- BCYC income statement
- BCYC valuation and score
- FHTX stock overview
- FHTX income statement
- FHTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.